CDK6/9-IN-2

• Description:

  CDK6/9-IN-2 is a highly active dual inhibitor of CDK6 (IC50 = 15 nM) and CDK9 (IC50 = 22 nM) . CDK6/9-IN-2 is selective for CDK2, CDK8, and CDK11. CDK6/9-IN-2 inhibits the proliferation of HaCaT cells induced by IFN-γ/TNF-α and suppresses the STAT3 pathway and the expression of inflammatory factors. CDK6/9-IN-2 can alleviate psoriatic dermatitis and is useful in psoriasis research[1].

• UNSPSC:

  12352005

• Target:

  CDK; Interleukin Related; STAT

• Related Pathways:

  Cell Cycle/DNA Damage; Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Inflammation/Immunology

• Smiles:

  CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(NC4=CC=C(C=C4)N5CC[C@@H](C5)O)=N3)Cl

• Molecular Formula:

  C25H30ClN7O

• Molecular Weight:

  480.01

• References & Citations:

  [1]Ru Y, et al. Dual CDK6 and CDK9 inhibitors as anti-psoriasis agents: Design, synthesis, and anti-inflammatory activity. Bioorg Med Chem Lett. 2025 Nov 1;127:130316.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK6; CDK9; IL-1; IL-6; IL-8; STAT3

• CAS Number:

  [3068529-24-5]